Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

Impact · against what's priced in

Moderna and Merck have achieved a critical clinical milestone with their personalized cancer vaccine, providing a proof-of-concept for a new treatment class. While the results are fundamentally positive, the market had already largely anticipated the potential for this platform to expand into other cancer types.

MRNA+0.70

No priced-in read yet